Higher clearance of micafungin in neonates compared with adults: Role of age-dependent micafungin serum binding

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 4, 2011, Pages 222-232

  Yanni, Souzan B ^a,b   Smith, P Brian ^c   Benjamin Jr , Daniel K ^c   Augustijns, Patrick F ^b   Thakker, Dhiren R ^a   Annaert, Pieter P ^b  

^a University of North Carolina   (United States)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

antifungal; clearance prediction; micafungin; pediatric drug disposition; serum binding

Indexed keywords

BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC ANION TRANSPORTER 1; PEPTIDE DERIVATIVE; SODIUM TAUROCHOLATE COTRANSPORTING PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY EXCRETION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG PROTEIN BINDING; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; NEWBORN; PROTEIN EXPRESSION;

ADULT; AGE FACTORS; ANTIFUNGAL AGENTS; BILIARY TRACT; BLOOD PROTEINS; ECHINOCANDINS; HUMANS; INFANT, NEWBORN; LIPOPEPTIDES; LIVER; ORGANIC ANION TRANSPORTERS; PROTEIN BINDING; SYMPORTERS;

EID: 79955074075     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.752     Document Type: Article

References (41)

1. Hebert MF, Townsend RW, Austin S, et al., Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954-960. (Pubitemid 41060236)
2. Kaneko H, Yamato Y, Teramura Y, et al., Metabolites of micafungin in rats and dogs. Jpn J Chemother 2002; 50 (Suppl. 1): 88-93. (Pubitemid 36033014)
3. Yamato Y, Kaneko H, Hashimoto T, et al,. Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jpn J Chemother 2002; 50 (Suppl. 1): 74-79. (Pubitemid 36033012)
4. Carver PL,. Micafungin. Ann Pharmacother 2004; 38: 1707-1721. (Pubitemid 39297772)
5. Heresi GP, Gerstmann DR, Reed MD, et al., The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis 2006; 25: 1110-1115. (Pubitemid 44900673)
6. Wiederhold NP, Lewis II JS,. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007; 8: 1155-1166. (Pubitemid 46929308)
7. Hope WW, Smith PB, Arrieta A, et al,. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54: 2633-2637.
8. Yanni SB, Augustijns P, Benjamin Jr DK, Brouwer KLR, Thakker DR, Annaert PP,. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos 2010; 38: 1848-1856.
9. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KLR,. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 2004; 311: 1203-1210. (Pubitemid 39612728)
10. Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KLR,. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999; 27: 637-644. (Pubitemid 29252436)
11. Ghibellini G, Vasist LS, Leslie EM, et al., In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 2007; 81: 406-413. (Pubitemid 46364478)
12. McNamara P, Alcorn J,. Protein binding predictions in infants. Pharm Sci 2002; 4: 1-8.
13. Lombardo F, Obach RS, Shalaeva MY, Gao F,. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002; 45: 2867-2876. (Pubitemid 34627657)
14. Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I,. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab Dispos 2008; 36: 1275-1282. (Pubitemid 351929311)
15. Benedetti MS, Whomsley R, Eugene Baltes LE,. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005; 1: 447-471.
16. Björkman S,. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2004; 59: 691-704. (Pubitemid 40835503)
17. Kalvass JC, Maurer TS,. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 327-338. (Pubitemid 36124162)
18. Barter ZE, Bayliss MK, Beaune PH, et al., Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45. (Pubitemid 46043890)
19. Chandra P, Lecluyse EL, Brouwer KLR,. Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 2001; 37: 380-385. (Pubitemid 32756849)
20. Annaert PP, Brouwer KLR,. Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2005; 33: 388-394. (Pubitemid 40279939)
21. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KLR,. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 2005; 83: 207-214. (Pubitemid 40227890)
22. McRae MP, Lowe CM, Tian X, et al,. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 2006; 318: 1068-1075. (Pubitemid 44268312)
23. Pinto N, Halachmi N, Verjee Z, Woodland C, Klein J, Koren G,. Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. Pediatr Res 2005; 58: 1284-1292.
24. Goralski KB, Acott PD, Fraser AD, Worth D, Sinal CJ,. Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Drug Metab Dispos 2006; 34: 288-295. (Pubitemid 43145030)
25. Hardikar W, Ananthanarayanan M, Suchy FJ,. Differential ontogenic regulation of basolateral and canalicular bile acid transport proteins in rat liver. J Biol Chem 1995; 270: 20841-20846.
26. Chen HL, Chen HL, Liu YJ, et al,. Developmental expression of canalicular transporter genes in human liver. J Hepatol 2005; 43: 472-477.
27. Chen HL, Liu YJ, Feng CH, et al., Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008; 63: 15-21.
28. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF,. ABC transporter (P-gp/ABCB1, RP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39: 211-218.
29. Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E,. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. Inflamm Bowel Dis 2005; 12: 745-749. (Pubitemid 44253759)
30. Gao B, Pierre MV, Stieger B, Meier PJ,. Differential expression of bile salt and organic anion transporters in developing rat liver. J Hepatol 2004; 41: 201-208. (Pubitemid 39177622)
31. Abe F, Ueyama J, Kawasumi N, et al,. Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats. Antimicrob Agents Chemother 2008; 52: 3454-3460.
32. Anderson BJ, Allegaert K,. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol 2010; 24: 419-431.
33. Anderson GD, Lynn AM,. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009; 29: 680-690.
34. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin Jr DK, Thakker DR,. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase. Drug Metab Dispos 2010; 38: 25-31.
35. Stone JA, Xu X, Winchell GA, et al,. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-823. (Pubitemid 38280330)
36. Sáez-Llorens X, Macias M, Maiya P, et al,. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53: 869-875.
37. Regazzi M, Perotti G, Pellegrini C, et al,. Two-year follow-up of the pharmacokinetics of immunosuppressive drugs in a neonate who underwent heart transplantation. J Matern Fetal Neonatal Med 2009; 22 (Suppl. 3): 108-110.
38. Akhlaghi F, Trull AK,. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002; 41: 615-637.
39. Rolan PE,. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-128. (Pubitemid 24213753)
40. Benet LZ, Hoener BA,. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121. (Pubitemid 34271114)
41. Piovan D, Padrini R, Svalato Moreolo G, et al., Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Ther Drug Monit 1995; 17: 60-67.